Status:
UNKNOWN
Parvovirus B19 Infection in Hereditary Hemolytic Anemias Patients
Lead Sponsor:
Sohag University
Collaborating Sponsors:
Assiut University
Conditions:
Parvovirus B19 Infection
Eligibility:
All Genders
12+ years
Brief Summary
Although many studies investigated the prevalence and manifestations of HPV-B19 infection in patients with sickle cell anemia (SCA), thalassemia, and hereditary spherocytosis (HS) separately, there is...
Detailed Description
HPV-B19 is the smallest single-stranded, linear DNA virus that causes human diseases. Exposure to respiratory secretions is the most common means of transmission of this virus. Infection is associated...
Eligibility Criteria
Inclusion
- Confirmed hereditary hemolytic anemias patients (age above 12 years) presented with signs and symptoms of hereditary hemolytic anemia (HHA) and admitted or treated in emergency departments or Hematology Units at Internal Medicine Departments of various university hospitals will be screened for enrollment in this study.
Exclusion
- • Patients will be diagnosed with non-HHA as ( autoimmune hemolytic anemia, microangiopathic hemolytic anemia (MAHA), Wilson disease, paroxysmal nocturnal hemoglobinuria (PNH).
- HHA-patients will refuse to consent to this study.
- Serologic evidence of recent virus infection other than human parvovirus B19 (HPV-B19); hepatitis A (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV,) cytomegalovirus (CMV), Epstein-Barr virus (EBV), or positive test for HIV.
- HHA patients with uncontrolled diabetes mellitus (DM).
- HHA patients with a history of nephrotic syndrome or chronic kidney disease(CKD).
- HHA patients with a history of treatment by immunosuppressive drugs.
- HHA patients with clinical and laboratory evidence of relevant toxicity related to iron chelation.
- HHA patients with severe systemic diseases (such as cardiovascular, renal, and hepatic disease) or surgical/medical conditions that might interfere with follow-up instructions.
- HHA patients with a life expectancy of less than 1 year.
- HHA patients with psychiatric disorders or a history of drug abuse,
- Pregnant women will be also excluded.
- Patients are not a candidate for investigation (Refusal
Key Trial Info
Start Date :
February 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 10 2024
Estimated Enrollment :
244 Patients enrolled
Trial Details
Trial ID
NCT04822090
Start Date
February 10 2018
End Date
February 10 2024
Last Update
March 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
, Faculty of Medicine, Sohag University
Sohag, Egypt, 82524